In the 6-month remission induction phase, 197 patients with GPA and MPA were randomized to either rituximab 375 mg/ m2 once weekly for 4 weeks plus glucocorticoids, or oral cyclophosphamide 2 mg/kg daily (adjusted for renal function, white blood cell count, and other factors) plus glucocorticoids to induce remission.